Human aldose reductase expression accelerates atherosclerosis in diabetic apolipoprotein E-/-Mice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 8, 2011, Pages 1805-1813

  Vedantham, Srinivasan ^a   Noh, Hyelim ^b   Ananthakrishnan, Radha ^a   Son, Ni ^b   Hallam, Kellie ^b   Hu, Yunying ^b   Yu, Shuiquing ^b   Shen, Xiaoping ^a   Rosario, Rosa ^a   Lu, Yan ^a   Ravindranath, Thyyar ^c   Drosatos, Konstantinos ^b   Huggins, Lesley Ann ^b   Schmidt, Ann Marie ^a   Goldberg, Ira J ^b   Ramasamy, Ravichandran ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b Division of Preventive Medicine and Nutrition   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

aldose reductase; atherosclerosis; diabetes mellitus; endothelial function

Indexed keywords

ALDEHYDE REDUCTASE; ANGIOPOIETIN RECEPTOR; APOLIPOPROTEIN E; GLUCOSE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; AORTA; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STREPTOZOCIN DIABETES; TRIACYLGLYCEROL BLOOD LEVEL; VASODILATATION;

ALDEHYDE REDUCTASE; ANIMALS; ATHEROSCLEROSIS; BASE SEQUENCE; CELL LINE; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; DNA, COMPLEMENTARY; ENDOTHELIAL CELLS; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION; GLUCOSE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; RECOMBINANT PROTEINS; RNA, SMALL INTERFERING; VASODILATION;

EID: 80051550208     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.111.226902     Document Type: Article

References (33)

1. Ramasamy R, Goldberg IJ. Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model. Circ Res. 2010;106:1449-1458.
2. Gleissner CA, Sanders JM, Nadler J, Ley K. Upregulation of aldose reductase during foam cell formation as possible link among diabetes, hyperlipidemia, and atherosclerosis. Arterioscler Thromb Vasc Biol. 2008;28:1137-1143.
3. Vikramadithyan RK, Hu Y, Noh HL, Liang CP, Hallam K, Tall AR, Ramasamy R, Goldberg IJ. Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J Clin Invest. 2005; 115:2434-2443. (Pubitemid 41266205)
4. Ho HT, Chung SK, Law JW, Ko BC, Tam SC, Brooks HL, Knepper MA, Chung SS. Aldose reductase-deficient mice develop nephrogenic diabetes insipidus. Mol Cell Biol. 2000;20:5840-5846. (Pubitemid 30613033)
5. Srivastava S, Vladykovskaya E, Barski OA, Spite M, Kaiserova K, Petrash JM, Chung SS, Hunt G, Dawn B, Bhatnagar A. Aldose reductase protects against early atherosclerotic lesion formation in apolipoprotein E-null mice. Circ Res. 2009;105:793-802.
6. Srivastava S, Spite M, Trent JO, West MB, Ahmed Y, Bhatnagar A. Aldose reductase-catalyzed reduction of aldehyde phospholipids. J Biol Chem. 2004;279:53395-53406. (Pubitemid 40063546)
7. Ramasamy R, Oates PJ, Schaefer S. Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury. Diabetes. 1997; 46:292-300. (Pubitemid 27272264)
8. Nishimura C, Matsuura Y, Kokai Y, Akera T, Carper D, Morjana N, Lyons C, Flynn TG. Cloning and expression of human aldose reductase. J Biol Chem. 1990;265:9788-9792.
9. Yamaoka T, Nishimura C, Yamashita K, Itakura M, Yamada T, Fujimoto J, Kokai Y. Acute onset of diabetic pathological changes in transgenic mice with human aldose reductase cDNA. Diabetologia. 1995;38:255-261.
10. Hwang YC, Sato S, Tsai JY, Yan S, Bakr S, Zhang H, Oates PJ, Ramasamy R. Aldose reductase activation is a key component of myocardial response to ischemia. FASEB J. 2002;16:243-245.
11. Ohashi M, Runge MS, Faraci FM, Heistad DD. MnSOD deficiency increases endothelial dysfunction in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2006;26:2331-2336. (Pubitemid 44465730)
12. Laursen JB, Somers M, Kurz S, McCann L, Warnholtz A, Freeman BA, Tarpey M, Fukai T, Harrison DG. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation. 2001;103:1282-1288. (Pubitemid 32221353)
13. Hein TW, Liao JC, Kuo L. oxLDL specifically impairs endotheliumdependent, NO-mediated dilation of coronary arterioles. Am J Physiol Heart Circ Physiol. 2000;278:H175-H183. (Pubitemid 30101869)
14. Heinecke JW, Kawamura M, Suzuki L, Chait A. Oxidation of low density lipoprotein by thiols: superoxide-dependent and-independent mechanisms. J Lipid Res. 1993;34:2051-2061. (Pubitemid 24000954)
15. Harja E, Chang JS, Lu Y, Leitges M, Zou YS, Schmidt AM, Yan SF. Mice deficient in PKC and apolipoprotein E display decreased atherosclerosis. FASEB J. 2009;23:1081-1091.
16. Kobayashi M, Inoue K, Warabi E, Minami T, Kodama T. A simple method of isolating mouse aortic endothelial cells. J Atheroscler Thromb. 2005;12:138-142.
17. Li Q, Hwang YC, Ananthakrishnan R, Oates PJ, Guberski D, Ramasamy R. Polyol pathway and modulation of ischemia-reperfusion injury in Type 2 diabetic BBZ rat hearts. Cardiovasc Diabetol. 2008;7:33.
18. Morre DM, Lenaz G, Morre DJ. Surface oxidase and oxidative stress propagation in aging. J Exp Biol. 2000;203:1513-1521. (Pubitemid 30354721)
19. Cheng HM, Gonzalez RG. The effect of high glucose and oxidative stress on lens metabolism, aldose reductase, and senile cataractogenesis. Metabolism. 1986;35:10-14. (Pubitemid 16104316)
20. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-820. (Pubitemid 34000785)
21. Nakashima Y, Raines EW, Plump AS, Breslow JL, Ross R. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. Arterioscler Thromb Vasc Biol. 1998; 18:842-851. (Pubitemid 28267666)
22. Harja E, Bu DX, Hudson BI, Chang JS, Shen X, Hallam K, Kalea AZ, Lu Y, Rosario RH, Oruganti S, Nikolla Z, Belov D, Lalla E, Ramasamy R, Yan SF, Schmidt AM. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/-mice. J Clin Invest. 2008;118:183-194.
23. Dan Q, Wong R, Chung SK, Chung SS, Lam KS. Interaction between the polyol pathway and non-enzymatic glycation on aortic smooth muscle cell migration and monocyte adhesion. Life Sci. 2004;76:445-459. (Pubitemid 39458312)
24. Tesfamariam B, Palacino JJ, Weisbrod RM, Cohen RA. Aldose reductase inhibition restores endothelial cell function in diabetic rabbit aorta. J Cardiovasc Pharmacol. 1993;21:205-211. (Pubitemid 23027595)
25. Cameron NE, Cotter MA. Impaired contraction and relaxation in aorta from streptozotocin-diabetic rats: role of polyol pathway. Diabetologia. 1992;35:1011-1019.
26. Cameron NE, Cotter MA. Contraction and relaxation of aortas from galactosaemic rats and the effects of aldose reductase inhibition. Eur J Pharmacol. 1993;243:47-53. (Pubitemid 23300541)
27. Johansson F, Kramer F, Barnhart S, Kanter JE, Vaisar T, Merrill RD, Geng L, Oka K, Chan L, Chait A, Heinecke JW, Bornfeldt KE. Type 1 diabetes promotes disruption of advanced atherosclerotic lesions in LDL receptor-deficient mice. Proc Natl Acad Sci USA. 2008;105:2082-2087. (Pubitemid 351439468)
28. Noh HL, Hu Y, Park TS, DiCioccio T, Nichols AJ, Okajima K, Homma S, Goldberg IJ. Regulation of plasma fructose and mortality in mice by the aldose reductase inhibitor lidorestat. J Pharmacol Exp Ther. 2009; 328:496-503.
29. Ramana KV, Bhatnagar A, Srivastava SK. Inhibition of aldose reductase attenuates TNF-α-induced expression of adhesion molecules in endothelial cells. FASEB J. 2004;18:1209-1218. (Pubitemid 39006883)
30. Mylari BL, Beyer TA, Siegel TW. A highly specific aldose reductase inhibitor, ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate, and its congeners. J Med Chem. 1991;34(3):1011-1018.
31. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353: 2643-2653. (Pubitemid 41817713)
32. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572. (Pubitemid 351831357)
33. Hsueh W, Abel ED, Breslow JL, Maeda N, Davis RC, Fisher EA, Dansky H, McClain DA, McIndoe R, Wassef MK, Rabadan-Diehl C, Goldberg IJ. Recipes for creating animal models of diabetic cardiovascular disease. Circ Res. 2007;100:1415-1427. (Pubitemid 46834754)